NMSO3, a sulphated sialyl lipid, was evaluated for its efficacy against human immunodeficiency virus type 1 (HIV-1). The compound exhibited concentration-dependent inhibition of HIV-1 replication in primary infection cell culture systems. Substantial inhibition was observed at concentrations of NMSO3 that showed little cytotoxicity. NMSO3 also exhibited anti HIV-1 activity in chronically HIV-1 infected cultures. The production of progeny viruses was completely abolished without cytotoxicity by continuous addition of NMSO3 to chronically infected U937 cells. Furthermore, in attempting to define the inhibitory mechanism of NMSO3, we investigated its effect on several steps of the HIV-1 replication cycle. NMSO3 competes with gp120 for binding to CD4 receptors on cells and
Introduction
Mixtures containing the cells, NMSO3 and HIV-1 were incubated for 90 min at 37°C to permit adsorption of viral particles and then expanded 1:10 with fresh media. On day 6, samples were harvested for i) reverse transcriptase (RT) assay (Hoffman et al., 1985) , ii) p24 enzyme-linked immunosorbent assay (ELISA), to quantify the number of progeny viruses, and iii) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Twentyman & Luscombe, 1987) , to evaluate the number of viable cells. For assessment of the effects of NMSO3 in chronically HIV-1-infected U937 cells, the cells were seeded at 1.5× 10 5 /ml in a 24-well plate in the presence of NMSO3 (10 µg/ml). The cells were split 1:10 every 3-4 days with adding 10 µg/ml of NMSO3. The amount of virus produced was monitored twice a week by measuring RT activity.
Inhibition of gp120 binding to CD4 receptors
One hundred microlitres of recombinant soluble CD4 (Intracel, MA, USA) at 1.5 µg/ml in carbonate buffer was coated to each well of Immulon4 plate (Nunc InterMed) at 37°C for 1 h. The plate was gently immersed and repeatedly washed. After blocking to saturate protein reactive sites with 5% normal goat serum in phosphate buffered saline (PBS) at 37°C for 1 h, serially diluted NMSO3 with 150 ng of recombinant gp120 (rgp120) was added. Recombinant gp120 alone was added as the 100% binding control and blocking buffer alone was as the 0% binding control. The plate was incubated at room temperature for 1 h and then washed. One hundred microlitres of rabbit anti-rgp120 serum at 1:2000 dilution in blocking buffer was added and incubated at room temperature for 1 h. Horseradish peroxidase conjugated goat anti-rabbit IgG at 1:4000 dilution in blocking buffer was then added and incubated at room temperature for 1 h. Finally, ortho-phenylene diamine substrate was added, and reactivity was determined by monitoring optical density at 492 nm and 630 nm.
Epitope analysis against CD4 receptors
Peripheral blood mononuclear cells (PBMCs) (1×10 6 ) were preincubated with 100 µg/ml of NMSO3 at 37°C for 30 min, and then fluorescence isothiocyanate (FITC) conjugated monoclonal antibodies, which recognize the epitopes on the CD4 molecule, were added and incubated for 30 min on ice. After washing, fluorescence intensity of the cells was recorded in the log mode with fluorescence-activated cell sorter (FACS). The monoclonal antibodies used in this study were RPA-T4 (BD Biosciences, San Jose, CA, USA), OKT4A (BD Biosciences), and OKT4 (BD Biosciences).
Semi-quantitative RT-PCR of HIV-1 RNA
To examine the effect of NMSO3 on HIV-1 gene transcription, we analysed the expression of HIV env mRNA in cells by RT-PCR. Briefly, RNA was extracted from the chronically HIV-1-infected H9 cells treated without or with NMSO3 (100 µg/ml) or AZT (100 µg/ml) by RNeasy kit (Qiagen, Germany). Then, 200 ng of RNA was reverse transcribed with Omniscript (Qiagen, Germany) and subjected to PCR using specific oligonucleotide primers. We used the primer pair, designed to flank the common splice donor and acceptor sites of env, as previously reported by Davis et al. (2001) . The sequences of primers were 5′−tagtactgcagtctcgacgcaggactcggc-3′ and 5′-gaatctagatcccaaggagcatggtgcc-3′. Human glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA (Apostolakos et al., 1993 ) was co-amplified as an internal control, and the primers used were 5′-gaaggtgaaggtcggagtc-3′ and 5′-gaagatggtgatgggatt-3′ (Taqman PCR Reagent Kit Protocol, PE Applied Biosynthesis). Reaction mixtures were heated to 95°C for 5 min, and then cycled 26 times; each cycle consisted of denaturation at 95°C for 30 sec, annealing at 57°C (env) or 62°C (GAPDH) for 30 sec, and strand elongation at 72°C for 30 sec. The amplified products were analysed by 2% agarose gel electrophoresis, and the intensity of each band was calibrated by the NIH image.
Results

Inhibitory effect of NMSO3 on HIV-1 primary infection
H9 cells were pretreated with various concentrations of NMSO3 and then inoculated with HIV-1. Infection and viral replication were monitored by measuring the amount of progeny viruses by the activity of reverse transcriptase and the amount of p24 antigens. As shown in Figure 2A , NMSO3 treatment resulted in a concentration-dependent inhibition of HIV-1 (III B and MN) replication in this primary assay system, and 50% effective concentration (EC 50 ) was observed at 1.5 µg/ml for III B and 2 µg/ml for MN. No cytotoxicity was observed at concentrations up to 100 µg/ml (data not shown). We also examined viral production by measuring the level of p24 antigens. Figure 2B shows ©2003 Anti HIV activity on chronic infection NMSO3 treatment also inhibited viral replication in U937 cells chronically infected with HIV-1 (III B ). As confirmed by FACS analysis, 100% of the cells were infected (data not shown). The production of progeny viruses started diminishing after approximately 1 month of NMSO3 treatment and was completely abolished after 90 days ( Figure 3 ). Complete inhibition of viral replication was maintained as long as NMSO3 was present in culture media. No effect on cell viability was observed, and the culture without NMSO3 showed continuous virus production during the entire period of the experiment (data not shown). Furthermore, the effect of NMSO3 was reversibly affected. When NMSO3 treatment was neglected, RT activity appeared again in the culture supernatants of previous nonproducing cells.
Competition analysis against CD4 receptors
To determine the mechanism of action of NMSO3 on HIV-1 replication, we first examined an initial step of HIV-1 infection, the binding of gp120 to CD4 receptor. We performed the blocking assay with NMSO3 to evaluate its inhibitory effect on the binding between rgp120 and immobilized CD4. As shown in Figure 4 , NMSO3 exhibited concentration-dependent inhibition of rgp120 binding to recombinant soluble CD4 (rsCD4). This result indicates that NMSO3 can protect CD4 receptors from HIV-1 binding. The control experiment with AZT exhibited no inhibition of rgp120 binding to rsCD4.
To confirm the precise domain participating in NMSO3 inhibition, we next performed the epitope analysis by the competition ratios between NMSO3 and anti-CD4 monoclonal antibodies toward the CD4 molecule. The RPA-T4 antibody recognizes the immunoglobulin (Ig) Figure 3 . Effect of NMSO3 on HIV-1 replication in chronically infected cells* complementary determining region (CDR)-1-and CDR3like region, and OKT4A does the CDR2-like region of the D1 domain of the CD4 receptor, respectively. As shown in Figure 5 , the binding activities of RPA-T4 and OKT4A to the CD4 molecule on the cells were completely blocked by NMSO3. In contrast, partial inhibition was observed with OKT4 antibody, which recognizes D2 domain of CD4. NMSO3 had no effect on the binding of anti-CXCR4 antibody (data not shown).
These findings demonstrate that NMSO3 interacts with the CD4 molecule, especially in the D1 domain of CD4, and exhibits the inhibitory activity toward the binding between gp120 and CD4.
Analysis of HIV-1 gene transcription with NMSO3
To investigate another mechanism of action against HIV-1, especially to distinguish the inhibitory mechanism in chronic infection, we studied the inhibitory effect of NMSO3 on HIV-1 transcription by semi-quantitative RT-PCR. To examine the levels of HIV-1 mRNA expression, total RNA was extracted from the infected cells treated with NMSO3 or AZT and subjected to RT-PCR using a specific primer pair that amplifies the splice donor and acceptor sites of the env gene. The RT-PCR products were then analysed using the NIH image after 2% agarose gel electrophoresis. As an internal control for variation in a single experiment, GAPDH mRNA was also amplified and viral specific bands were normalized comparing the intensity of the GAPDH mRNAs. As shown in Figure 6 , env mRNA was significantly reduced by NMSO3 treatment. The cells treated with NMSO3 did express a small amount of HIV-1 spliced mRNA. In contrast, AZT treatment had no effect on HIV-1 gene expression. These results suggest that NMSO3 treatment also suppresses the transcription from HIV-1 proviruses. Nakamura et al.
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©2003 International Medical Press . Inhibition of rgp120 binding to CD4 by NMSO3* *Serially diluted NMSO3 or AZT was mixed with 150 ng of rgp120 and added to the soluble CD4 coated plate. The amount of bound rgp120 was determined by ELISA.
Discussion
Each step of the HIV-1 replication cycle could theoretically serve as a target for therapeutic intervention. Advances in the understanding of the replication cycle have revealed which events can be selectively inhibited. Although HAART has made significant progress with the development of several promising agents (Debul et al., 2001) , additional agents with distinct mechanisms of action are still needed for effective anti-HIV-1 therapy. Furthermore, the importance of being able to treat chronic infection is anticipated from the pathology of HIV-1 infection in vivo (Koup, 2001) .
NMSO3 was previously shown to be an effective agent against respiratory syncytial virus infection in vitro and in vivo. In this study, we have addressed that NMSO3 also has a potent antiviral activity against HIV-1. It is effective in both primary and chronic infection without cytotoxicity.
Studies by competition ELISA revealed that NMSO3 selectively blocked the CD4/gp120 binding. It was shown that soluble CD4 and gp120 bound tightly, and molecules blocking this interaction could also inhibit HIV-1 infection and cell membrane fusion (Hussey et al. 1988) . Previous studies reported that dextran sulphate bound to the gp120 V3 region through its high anionic charge and blocked the subsequent entry process of virus into cells (Moulard et al., 2000) . NMSO3 has a structure similar to dextran sulphate (highly anionic charges in a polysulphate part). Moreover, it is generally known that negatively charged polysaccharides inhibit viral adsorption to cell membranes by interfering with static electric binding between viral envelopes and cell membranes (Mastromarino et al., 1997) . NMSO3 has four sulphate residues in a molecule. It is negatively charged and may inhibit the binding of HIV-1 to the CD4 receptor. Therefore, it is suggested that NMSO3 interacts with CD4, and one of the mechanistic effects of NMSO3 in primary infection seems to be the inhibition of the binding of gp120 and CD4, resulting in the termination of HIV-1 replication at the viral entry stage.
CD4 consists of four extracellular domains. There are three CDR-like regions in the D1 domain (Peterson & Seed, 1988) . By the competition analysis for the CD4 receptor, NMSO3 showed complete competition with monoclonal antibodies that recognize the D1 domain of CD4. Specifically, RPA-T4, which is specific for the Ig CDR-1 and -3-like regions of the CD4 molecule and OKT4A recognizing the CDR2-like region, showed a strong competitive ability with NMSO3. However, OKT4 was revealed to be less competitive. No reaction was observed with the monoclonal antibody against CXCR4 (Endres et al., 1996) . CDR2 was identified as gp120 binding site (Clayton et al., 1989) , and OKT4A is also known to have a competitive ability with HIV to CD4 (Arthos et al. 1990 ). Based on these findings, the anti-HIV-1 activity of NMSO3 appears to depend on the interaction of gp120 with the CD4 receptor, especially the D1 domain of CD4.
Since NMSO3 also inhibits the production of progeny viruses in chronically infected U937 cells, we addressed the possibility of whether this agent had an additional mechanism of action. To investigate a direct proof for the inhibitory effect in chronic infection, we examined viral expression in the presence of NMSO3. The inhibition of viral transcription was shown by semi-quantitative RT-PCR. Benkirane et al. (1993) have reported that monoclonal antibody 13B8-2, which is specific for the CDR3-like region in domain 1 of CD4, inhibits HIV-1 provirus transcription (Briant et al., 1997) . The cytoplasmic tail of CD4 was required for such inhibition (Benkirane et al. 1995) and the antibody treatment inhibited the activation of MAPK induced in HIV-1 infected cells (Schmid-Antomarchi et al., 1996) . Therefore, we assume that the mechanism of action of NMSO3 is comparable with that of 13B8-2, since NMSO3 can interact with the CDR3-like region in the D1 domain of CD4, and the inhibition of HIV-1 transcription corresponds to the inactivation of signalling pathways participating in the regulation of HIV-1 progeny production.
In summary, the anti-HIV-1 activity of NMSO3 is attributed to both binding inhibition during primary infection and transcription inhibition of proviral DNA. Therefore, we conclude that NMSO3 is a promising agent effective in both primary and chronic HIV-1 infections. Figure 6 . Inhibition of HIV-1 gene transcription by NMSO3* *HIV-1 infected H9 cells were treated with NMSO3 or AZT for 72 h, and then RNA was purified and reverse transcribed. PCR was performed for HIV-1 env and GAPDH genes. The amplified products were analysed by electrophoresis, and the intensities were calibrated by the NIH image. The table indicates the intensities of each signal.
